Read the result in context
Evidence
Start with who was studied and what was measured.
A result about deep belly fat does not describe every goal a person might bring to a visit.
- Placebo
- A dummy treatment used for comparison with the medicine.
What the main trials found
The first main trial enrolled 412 adults with HIV who had excess belly fat.
HIV is short for human immunodeficiency virus.
In that trial’s published paper, deep belly fat fell 15.2% with tesamorelin and rose 5.0% with placebo over 26 weeks.
The next trial enrolled 404 adults and found a 10.9% fall with tesamorelin, compared with a 0.6% fall with placebo.
These are group results; they do not predict a particular person’s result.
- Visceral fat
- The deep fat around the belly’s organs.
What happened after the switch
In both main trials, some participants changed from tesamorelin to placebo after 26 weeks.
They regained deep belly fat during the next 26 weeks.
That matters when asking what an ongoing care plan would involve.
Ask what the plan is if treatment ends.
- Study scope
- The people, purpose and length of time a study actually covers.
What the result does not settle
Weight changed very little in the main trials.
As of September 28, 2026, the tesamorelin label does not approve it for general weight loss.
The label also says it is not yet known how the heart and blood vessels are affected over the long term.
Ask for evidence that matches the goal being proposed for you.
